ArticleFrontiers in aging neuroscience2025
Blood biomarkers as surrogate endpoints in Alzheimer's disease research.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Statistical inference for saved time based on disease progression curves in Alzheimer's disease research.Contemporary clinical trials communications · 2026Article
- Longitudinal Change in Blood-Based Biomarkers and the Association With MRI-Measured Neurodegeneration in Cognitively Unimpaired Individuals.Neurology · 2026Observational
- Testing disease progression under the proportional reduction in decline in Alzheimer's disease studies.Journal of applied statistics · 2026Article
- Comparison between treatment-placebo difference and saved time measures to assess treatment effect in Alzheimer's disease.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: Blood biomarkers for Alzheimer's disease (AD) can be utilized as surrogate endpoints to accelerate therapeutic development for this condition. Methods: We assessed the association between short-term changes in blood biomarkers and long-term declines in cognitive and brain structure volume measures using the ADNI database, with a focus on amyloid- Results: A trend association was found between changes in the levels of plasma neurofilament light (NfL) at 12 months and changes in the scores on the Mini-Mental State Examination (MMSE) at 24 months in Aβ-positive mild cognitive impairment (MCI) patients. For A Conclusion: Increased plasma levels of NfL or p-tau181 blood biomarkers were found to be associated with reduced brain volumes and/or declined cognitive outcomes, suggesting that these blood biomarkers may have a predictive role in AD trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.